APA (7th ed.) Citation

SF, S., C, S., TF, C., M, S., DS, S., RK, L., . . . Marberger, M. J. (2011). Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: A decision-curve analysis. Cancer (0008543X), 117(13), 2892. https://doi.org/10.1002/cncr.25903

Chicago Style (17th ed.) Citation

SF, Shariat, et al. "Assessing the Clinical Benefit of Nuclear Matrix Protein 22 in the Surveillance of Patients with Nonmuscle-invasive Bladder Cancer and Negative Cytology: A Decision-curve Analysis." Cancer (0008543X) 117, no. 13 (2011): 2892. https://doi.org/10.1002/cncr.25903.

MLA (9th ed.) Citation

SF, Shariat, et al. "Assessing the Clinical Benefit of Nuclear Matrix Protein 22 in the Surveillance of Patients with Nonmuscle-invasive Bladder Cancer and Negative Cytology: A Decision-curve Analysis." Cancer (0008543X), vol. 117, no. 13, 2011, p. 2892, https://doi.org/10.1002/cncr.25903.